 - Ortho is the only company that offers laboratories in the U.S. a quantitative test in combination with a nucleocapsid test - Both new antibody tests help health care teams differentiate the cause of antibodies against SARS-CoV-2 - Orthos new VITROS Anti-SARS-CoV-2 IgG Quantitative Antibody test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians and public health leaders a standard tool to measure antibody response to SARS-CoV-2 RARITAN, N.J., May 21, 2021 PRNewswire -- Ortho Clinical Diagnostics Nasdaq: OCDX, one of the worlds largest pure-play in vitro diagnostics companies, today announced the launch of the first quantitative COVID-19 IgG antibody test in addition to a total COVID-19 nucleocapsid antibody test. 